Livzon Pharmaceutical Group Inc. (Livzon Pharma) released an announcement dated 29 May 2026 confirming the latest composition of its Board of Directors and five specialist committees—Audit, Remuneration and Assessment, Nomination, Strategy, and Environmental, Social & Governance (ESG).

Board composition • Executive Directors: President Liu Daping; Vice-Chairman Tang Yanggang. • Non-executive Directors: Chairman Zhu Baoguo; Lin Nanqi; Qiu Qingfeng. • Employee Representative Director: Ran Yongmei. • Independent Non-executive Directors (INEDs): Luo Huiyuan; Cui Lijie; Wang Zhiyao; Kang Li.

Committee highlights • Five Board committees remain in place, each covering key areas of governance, strategy, and oversight. • Chairman Zhu Baoguo holds chairmanships on two committees, underscoring his central role in board-level decision-making. • INED Kang Li chairs one committee and serves as a member on two others, reflecting the regulatory emphasis on independent oversight. • Vice-Chairman Tang Yanggang sits on four committees, indicating deep involvement in both operational and strategic matters. • INEDs Luo Huiyuan and Cui Lijie each hold a mix of chair and member positions, supporting board independence across critical functions. • INED Wang Zhiyao and Employee Representative Director Ran Yongmei serve as members on selected committees, providing additional expertise and employee perspectives.

The disclosure aligns with Hong Kong Listing Rules, offering investors and stakeholders full visibility into the governance structure guiding Livzon Pharma’s strategic, financial, and ESG initiatives.